Nyxoah SA (NYXH) Q4 2025 Earnings Call Transcript

Nyxoah held its Q4 and full-year 2025 earnings call on March 19, 2026, led by CEO Olivier Taelman and CFO John Landry; the company stated its Q4 2025 financial results were released after U.S. market close and the press release is on the IR website. The prepared remarks included standard forward-looking statement cautions. The provided excerpt contains no financial metrics, guidance, or operational details.

Analysis

The most overlooked second-order effect from Nyxoah’s story is the supply-chain leverage created by an implantable neuromodulation product that scales: contract manufacturers, lead/battery suppliers and sterility/packaging vendors will see lumpy but high-margin revenue flows tied to surgical cadence, not consumable replacement. That pattern rewards partners with flexible capacity and near-term working-capital exposure while penalizing vertically integrated incumbents that rely on recurring CPAP consumables. Hospitals and ambulatory surgical centers stand to capture outsized procedure-level margin shifts (one-time device reimbursement > multiple months of CPAP payer revenue), which changes referral economics for ENT and sleep surgeons and accelerates center-level incentives to push procedural therapies.

Execution risk centers on three binary levers that will move valuation materially: (1) timely, broad-based reimbursement coding/coverage decisions across major payers (weeks–months); (2) surgical throughput and implanter training bottlenecks at scale (3–12 months); and (3) manufacturing yield and component lead times for implanted batteries/electrodes (months). Clinical durability and real-world adherence data will be the 12–36 month inflection: if ≥12‑month registries show sustained AHI reductions and low device explant rates, adoption curves steepen; adverse safety signals or payer denials reverse the thesis quickly. Litigation/regulatory tail risk and cash-rollover dilution remain credible near-term downside paths.

The contrarian read: the market is discounting durable behavioral change in severe OSA management and is therefore pricing Nyxoah more like an early-stage R&D story than a commercial medtech growth play. If management can demonstrate repeatable implant volumes per trained implanter and two large-payer coverage wins in the next 6–12 months, the multiple should re-rate toward peer neuromodulation medtech (2–4x current). However, if supply or reimbursement slips, downside is steep because unit economics rely on fixed-cost leverage and low incremental COGS.

Key Decisions for Investors

• Long NYXH equity (size 1–2% portfolio): accumulate on any post-earnings weakness over next 2–6 weeks; set tactical stop-loss at -35% and a 12–24 month target of +150% conditional on two payer coverage wins or clear 12‑month RWD. Risk: binary reimbursement/manufacturing misses.
• Long-dated call spread (NYXH Jan-2028 50–150% OTM call spread financed by selling nearer-term calls): limited downside premium, asymmetric upside if adoption accelerates over 12–36 months; ideal if you expect dilution risk but want upside capture.
• Pair trade (long NYXH 1% / short INSP 0.4%): hedge sector- and macro-beta while expressing conviction that Nyxoah’s European commercial traction and lower upfront surgical complexity can re-rate faster than Inspire. Monitor relative-volume and reimbursement headlines weekly; unwind on divergence >30% vs entry.
• Event hedge: buy 3–6 month put protection sized to 30% of position value ahead of major reimbursement announcements or manufacturing milestones to cap short-term downside from binary negative outcomes.